Identification and characterization of an anti-fibrotic benzopyran compound isolated from mangrove-derived Streptomyces xiamenensis

Article abstract of DOI:10.3390/md10030639

An anti-fibrotic compound produced by Streptomyces xiamenensis, found in mangrove sediments, was investigated for possible therapeutic effects against fibrosis. The compound, N-[[3,4-dihydro-3S-hydroxy- 2S-methyl-2-(4′R- methyl-3′S-pentenyl)-2H- 1-benzopyran-6-yl]carbonyl]-threonine (1), was isolated from crude extracts and its structure, including the absolute configuration was determined by extensive spectroscopic data analyses, Mosher's method, Marfey's reagent and quantum mechanical calculations. In terms of biological effects, this compound inhibits the proliferation of human lung fibroblasts (WI26), blocks adhesion of human acute monocytic leukemia cells (THP-1) to a monolayer of WI26 cells, and reduces the contractile capacity of WI26 cells in three-dimensional free-floating collagen gels. Altogether, these data indicate that we have identified a bioactive alkaloid (1) with multiple inhibitory biological effects on lung excessive fibrotic characteristics, that are likely involved in fibrosis, suggesting that this molecule might indeed have therapeutic potential against fibrosis.

Full text of DOI:10.3390/md10030639

Mar. Drugs 2012, 10, 639-654; doi:10.3390/md10030639
OPEN ACCESS
Marine Drugs
ISSN 1660-3397
www.mdpi.com/journal/marinedrugs
Article
Identification and Characterization of an Anti-Fibrotic
Benzopyran Compound Isolated from Mangrove-Derived
Streptomyces xiamenensis
Min-Juan Xu 1,†, Xiao-Jin Liu 2,3,†, Yi-Lei Zhao 4, Dong Liu 5, Zhen-Hao Xu 4, Xiao-Meng Lang 5,
Ping Ao 1, Wen-Han Lin 5, Song-Lin Yang 2, Zhi-Gang Zhang 3,* and Jun Xu 4,*
1
Shanghai Center for Systems Biomedicine, Shanghai Jiao Tong University, Key Laboratory of
Systems Biomedicine, Shanghai 200240, China; E-Mails: minjuanxu@sjtu.edu.cn (M.-J.X.);
aoping@sjtu.edu.cn (P.A.)
2
Department of Plastic Surgery, Shanghai Jiaotong University Affiliated Sixth People’s Hospital,
Shanghai 200233, China; E-Mails: xjliu00058065@gmail.com (X.-J.L.);
yangsonglin1961@gmail.com (S.-L.Y.)
3
State Key Laboratory of Oncogenes and Related Genes, Shanghai Cancer Institute, Ren Ji Hospital,
Shanghai Jiao Tong University School of Medicine, Shanghai 200240, China
4
State Key Laboratory of Microbial Metabolism and School of Life Science & Biotechnology,
Shanghai JiaoTong University, Shanghai 200240, China; E-Mails: yileizhao@sjtu.edu.cn (Y.-L.Z.);
bao2lu@gmail.com (Z.-H.X.)
5
State Key Laboratory of Natural and Biomimetic Drugs, Peking University, Beijing 100191, China;
E-Mails: ldddddd@yahoo.cn (D.L.); lxmdyt112@sina.com (X.-M.L.);
whlin@bjmu.edu.cn (W.-H.L.)
†
These authors contributed equally to this work.
* Authors to whom correspondence should be addressed: E-Mails: zzhang@shsci.org (Z.-G.Z.);
xujunn@sjtu.edu.cn (J.X.); Tel.: +86-21-34206763 (Z.-G.Z.); +86-21-34207208 (J.X.);
Fax: +86-21-34206763 (Z.-G.Z.); +86-21-34207205 (J.X.).
Received: 21 January 2012; in revised form: 27 February 2012 / Accepted: 6 March 2012 /
Published: 15 March 2012
Abstract: An anti-fibrotic compound produced by Streptomyces xiamenensis, found in
mangrove sediments, was investigated for possible therapeutic effects against fibrosis.
The compound, N-[[3,4-dihydro-3S-hydroxy-2S-methyl-2-(4′R-methyl-3′S-pentenyl)-2H-
1-benzopyran-6-yl]carbonyl]-threonine (1), was isolated from crude extracts and its
structure, including the absolute configuration was determined by extensive spectroscopic
data analyses, Mosher’s method, Marfey’s reagent and quantum mechanical calculations.

Mar. Drugs 2012, 10
In terms of biological effects, this compound inhibits the proliferation of human lung
640
fibroblasts (WI26), blocks adhesion of human acute monocytic leukemia cells (THP-1) to a
monolayer of WI26 cells, and reduces the contractile capacity of WI26 cells in
three-dimensional free-floating collagen gels. Altogether, these data indicate that we have
identified a bioactive alkaloid (1) with multiple inhibitory biological effects on lung
excessive fibrotic characteristics, that are likely involved in fibrosis, suggesting that this
molecule might indeed have therapeutic potential against fibrosis.
Keywords: Streptomyces xiamenensis; mangrove; benzopyran; fibroblast; anti-fibrosis;
anti-contractile capacity
1. Introduction
Fibrotic diseases such as pulmonary fibrosis, cirrhosis, systemic sclerosis, interstitial nephritis and
cardiovascular fibrosis are a threat to public health [1]. Constant high exposure to respirable particles
is known to directly cause chronic inflammation-associated pulmonary diseases, including lung
fibrosis and lung cancer [2]. These observations have resulted in increased research into mechanisms
associated with fibrosis, the excessive fibrous connective tissue that underlies many chronic
inflammatory pulmonary pathologies [1]. Indeed, studies have suggested that about 45% of deaths in
developed countries are associated with fibrotic diseases of various organs [1].
Fibroblasts, one of the most abundant cells in the interstitial tissues, are known to play an important
role in inflammation and fibrogenesis [1,3]. Interactions between fibroblasts and the local
microenvironment can induce the formation of self-perpetuating circuits of inflammation [4]. These
circuits can maintain the prolonged and elevated excellular matrix (ECM) secreting phenotype of
fibroblasts, which is the defining characteristic of fibrotic diseases. Therefore, the search for leading
compounds, particularly those obtained from a natural resource, that target fibroblasts represents an
emerging pharmacological and therapeutic focus against fibrotic diseases.
Mangrove and its derived actinobacteria strains, are well-known for producing novel secondary
metabolites and possessing highly effective bioactive compounds, possibly due to biochemical
adaptation to the special intertidal ecosystem [5–9]. For example, in studies of anti-inflammatory
compounds, 7-deacetylgedunin from Xylocarpus moluccensis was found to inhibit nitric oxide
production in activated macrophages [10]. In another study, diterpenoids from Excoecaria agallocha L.
were observed to suppress expression of NF-κB and AP-1 (activating protein-1) targeted genes
including TNF-α and IL-6 in mouse macrophages [11]. Surfactin isomers from the mangrove
bacterium Bacillus sp. were also tested on the previous two models [12]. Finally, a mixture of
Acanthus ilicifolius leaf extract was also shown to exhibit inhibitory activity in rat paw edema [3]. The
immense and untapped microbial biodiversity in the mangrove is a promising resource for
marine-derived leading therapeutic compounds.
Streptomyces xiamenensis strain 318 was identified as a novel species of actinobacteria from
mangrove sediments [13]. During our preliminary screening for anti-fibrotic compounds, a crude
extract of S. xiamenensis was tested in an adhesion-bioassay of fibroblasts on monocytes, and showed

Mar. Drugs 2012, 10
641
inhibitory activity. Further studies were then carried out to identify and characterize the active
ingredient in this extract. In our work, an alkaloid, N-[[3,4-dihydro-3S-hydroxy-2S-methyl-2-(4′R-
methyl-3′S-pentenyl)-2H-1-benzopyran-6-yl]carbonyl]-threonine (1), was isolated from crude extracts
of S. xiamenensis (Figure 1.) and demonstrated to have considerable bioactivity. Compound 1 was
previously isolated from Streptomyces sp. Mer-88, and shown to inhibit binding between LFA-1 and
ICAM-1, and suggested to have important anti-inflammatory properties [14]. The absolute
configurations of compound 1, including four stereogenic centers, were determined by extensive
spectroscopic data analyses, Mosher’s method, Marfey’s reagent and quantum mechanical (QM)
calculations. Compound 1 was found to exhibit inhibitory effects on cell proliferation of human lung
fibroblasts (WI26), the contractile capacity of WI26 cells in a three-dimensional free-floating collagen
gels, and the adhesion of human acute monocytic leukemia cells (THP-1) on a WI26 monolayer. As
these properties are thought to contribute to the development of fibrosis, these data suggest that the
compound described herein might indeed prove to be of considerable therapeutic benefit against
fibrotic pathologies.
2. Results and Discussion
2.1. Isolation and Structural Elucidation of Compound 1
Crude extracts from S. xiamenensis were assayed for their inhibitory effect on the adhesion of THP-1
cells on a monolayer of WI26 cells. After incubating the crude extract (50 μg/mL) for 3 h, the adhesion
of the THP-1 cells was about 15% lower than that with the solvent control (0.01% DMSO). Thus, the
extract showed inhibitory adhesion activity and S. xiamenensis was considered as a promising
bioactive resource for further chemical analyses. Guided by this bioactivity, a series of alkaloids were
detected, using TLC and UPLC-MS, as the main secondary metabolites from the mixture extracted in a
solution of ethyl acetate: methanol: formic acid = 80:15:5. The presence of pseudo-molecular ions
[M + H]+ at m/z 392.2069 and [M − H]− at m/z 390.1886 in positive and negative ion modes,
respectively, in the mass spectra, led to the purification of the main component, compound 1.
Figure 1. Structure of compound 1 isolated from Streptomyces xiamenensis.
COOH
6'
HO 4'
NH
3'
4
14
CH3
6
4a
8a
5' H3C
3
OH
O
1'
2
10
12
O
CH3
13
9
8
11
CH3
15
1
The molecular formula of 1 is C21H29NO6 based on HRESIMS, which is in accordance with the
1
previous literature [14]. In the H NMR spectrum of 1, three aromatic protons with signals at δH 7.63
(1H, d, J = 8.4 Hz), 6.81 (1H, d, J = 8.4 Hz), 7.76 (1H, s), and 7.78, (1H, d, J = 7.8 Hz), as well as a
high-field double-bond proton at δH 5.12 (1H, dd, J = 7.1, 1.3 Hz) were detected (Table 1). Carbon
13
signals in the C NMR spectrum consisted of six aromatic carbons, plus two olefinic carbons, two

Mar. Drugs 2012, 10
642
carbonyl groups, two hydroxylated carbon signals at δC 79.8, 66.3, and a methylene at δC 31.2
(Table 1), which is in accordance with the structure of a benzopyran moeity, attached to two side
chains, threonine and isoprenylmethyl group. The HMBC correlations (Table 1) further confirmed the
planar structure of 1, named N-[[3,4-dihydro-3-hydroxy-2-methyl-2-(4′-methyl-3′-pentenyl)-2H-1-
benzopyran-6-yl]carbonyl]-threonine [14].
1
Table 1. H and 13C NMR spectroscopic data of compound 1 and ΔδRS values of key
H-atoms in (R)- and (S)-MPA diesters a.
1
R/S-MPA-1
Position
δH (J in Hz)
δC, type
--
HMBC
δR
δS
ΔδRS
1
2
3
--
--
79.8, C
66.3, CH
3.77, t b
4a, 2, 9, 15
2.71, dd (17.3, 7.4)
2.54
3.09
2.82
3.23
−0.28
−0.14
4
31.2, CH2
8a, 5, 4a, 2, 3
2.98, dd (17.3, 5.2)
4a
5
--
7.67, s
--
120.6, C
129.8, CH
126.0, C
7, 8a, 4, 1′
6
7
7.63, d (8.4)
6.81, d (8.4)
--
127.2, CH
116.7, CH
156.1, C
5, 8a, 1′
8
4a, 8a, 6
8a
1.55
1.47
2.05
5.01
1.29
1.21
1.95
4.89
+0.26
+0.26
+0.10
+0.12
9
1.60, m
38.0, CH2
11, 12, 2,3
10
11
12
13
14
15
1′
2.10, m
5.12, dd (7.1, 1.3)
--
21.6, CH2
124.8, CH
131.3, C
17.9, CH3
25.9, CH3
18.7, CH3
166.6, C
--
11, 12
13, 10, 14, 9
1.57, s
11
11
1.51
1.60
1.27
1.47
1.58
0.97
+0.04
+0.02
+0.30
1.65, s
1.18, s
2, 3, 9
--
2′
7.78, d (7.8)
4.38, brd
4.18, brs
1.12, d (6.0)
--
1′
8.29
4.81
8.40
4.84
−0.11
−0.03
3′
58.9, CH
67.1, CH
20.9, CH3
172.8, C
4′, 6′
4′
5′
1.27
1.10
+0.17
6′
a
b
Measured in DMSO-d6, Chemical shifts (δ) in ppm; Measured in [D4]-methanol, δH 3.88,
dd (7.4, 5.2).
2.2. Absolute Configurations of Compound 1
The absolute configurations of 1, with four stereogenic centers, were identified by Mosher’s
method, Marfey’s reagent, NOESY experiment, and QM calculations. Compound 1 was treated with
(R)- and (S)-α-methoxy-α-phenylacetic acid (MPA) to form (R)- and (S)-MPA diesters. Diagnostic
ΔδRS sigals of the (R)- and (S)-MPA diesters resulted in negative ΔδRS values for 4-H2 (Table 1), which

Mar. Drugs 2012, 10
643
were in contrast to the positive ΔδRS values for 9-H2, 10-H2, 11-H, 13-H3, 14-H3 and 15-H3, which are
all related to the dihydropyran moiety. These data are in accordance with a 3S configuration of 1. The
absolute configuration of the neighboring position 2 was then determined by elucidating the relative
configuration related to 3S. The NOE correlation between 2-H3 and 4-Ha demonstrated that 2-H3 was
in an axial orientation. The other NOE interaction between 2-H3 and 3-H demonstrated that 3-H was
equatorially oriented and 3-OH was in a trans configuration to 2-H3 (Figure 2). The relative
configuration of 2-H3, 3-H and 4-Ha/e were further confirmed from the values of the coupling
constants, which were 4-Ha (2.71, dd, 17.3, 7.4) and 4-He (2.98, dd, 17.3, 5.2).
Figure 2. Key NOE correlations of the dihydropyran moiety in compound 1.
CH3
S
2
2.71, dd, 17.3, 7.4
Ha
R
4
O
He
2.98, dd, 17.3, 5.2
H
3
S
NOE
R=side chain of C9-C14
OH
QM calculations on a model molecule of 2,2-dimethyl-3,4-dihydro-2H-pyran-3-ol indicate that,
compared to that at the equatorial position, the 3-OH group prefers the axial position by about
1.2 kcal/mol both in the gas phase and in DMSO solvent due to the gauche effect [15]. In the gauche
conformation, the H-H distances of 2-H3 are as close as 2.55 Å to 3-H, and 2.30 Å to 4-Ha. The results
are consistent with the key NOE correlations (Figure 2). Based on the absolute configuration of C-3
and the relative configuration of C-2, we therefore identified the absolute configuration of position 2 to
be 2S.
As far as the other two stereocenters in the threonine moiety, diagnostic ΔδRS sigals of the (R)- and
(S)-MPA diesters resulted in negative ΔδRS values for 3′-H and 2′-NH (Table 1), which were in
contrast to the positive ΔδRS values for 5′-H. The configuration of the position 4′ was thus assigned to
be R. In order to determine the configuration at the position 3′, 1 was hydrolyzed in hydrochloric acid
and then derivatized with 1-fluoro-2,4-dinitrophenyl-5-L-alanine (FDAA, Marfey’s reagent) [16].
Based on the results of hydrolyzation of 1 and derivatization with Marfey’s reagent afterwards, the
threonine moiety was assigned as the naturally occurring structure of L-threonine [(2S,3R)-2-amino-3-
hydroxy butanoic acid]. The absolute configuration of 1 was therefore determined to be
N-[[3,4-dihydro-3S-hydroxy-2S-methyl-2-(4′R-methyl-3′S-pentenyl)-2H-1-benzopyran-6-yl]carbonyl]-
threonine (1).
2.3. Inhibition of Proliferation on Human Diploid Lung Fibroblast (WI26) Cells by Compound 1.
Fibrosis is characterized by the overgrowth, hardening, and/or scarring of various tissues and is
attributed to an excess deposition of ECM components including collagen [1]. To combat this, an
ability to slow down rapid fibrotic response during typical wound repair and tissue regeneration
processes would seem to be a reasonable intervention, with the goal to avoid an accumulation of

Mar. Drugs 2012, 10
644
non-functional fibrotic tissue and thereby enable transformation to more regenerative conditions [3].
We thus investigated the anti-proliferative activity of 1 to this end. Lung fibroblast WI26 cells were
exposed to 1, at a concentration of 30 µg/mL, for 0, 2, 3, 4 and 6 days, and the optical density (OD)
λ = 450 nm was monitored as a function of time. As illustrated in Figure 3, compound 1 significantly
inhibited the proliferation of WI26 cells. The extent of this inhibition increased with time (Figure 3),
from a decrease of 7% at day 2 to 27% at day 6, compared with solvent control. Compound 1 therefore
indeed exhibits anti-proliferative effects on lung fibroblast cells.
Figure 3. Inhibitory effect of compound 1 on WI26 cells proliferation. The WI26 cells
were exposed to 30 µg/mL of 1 at day 0, 2, 3, 4 and 6. Surviving fraction was determined
by Cell Counting Kit-8 assay. As illustrated, proliferation of WI26 cells was significantly
inhibited by 1 in a time-dependent manner. Data are given as the mean of triplicate
values ± SD of three independent experiments. Significant differences from the value of
0.1% DMSO solvent control were marked ** p < 0.01, *** p < 0.001.
2.4. Effect of Compound 1 on the Adhesion of THP-1 Cells to a Monolayer of WI26 Cells
Monocytes and macrophages have been shown to play pivotal roles in inflammation and fibrosis by
modulating the secretion of cytokines as well as recruiting and activating fibroblasts and other
inflammatory cells [17]. Direct contact between monocytes/macrophages and fibroblasts is important
for the initiation, perpetuation, and resolution of fibrosis [18]. We therefore also evaluated the
anti-adhesion bioactivity of 1. WI26 cells were first grown as a cell monolayer on a rigid tissue culture
support, and then monocytic THP-1 cells were added to this monolayer. The number of adhered cells
was then measured by optical microscopy after a 3 h incubation with either 1 (30 μg/mL) or 0.1%
DMSO. As shown in Figure 4, there were obvious differences between the experiments with 1 present
compared with those of the solvent control (Figure 4). Namely, the adhesion of THP-1 was about 41%
lower in the presence of 1 than that in the solvent control. Thus, compound 1 exhibits significant
anti-adhesion bioactivity for monocytes on fibroblasts.

Mar. Drugs 2012, 10
Figure 4. Blocking adhesion of THP-1 cells onto a monolayer of WI26 cells by compound 1.
645
Representative pictures of the adhering cells taken with 400 fold magnification. Equal
numbers of THP-1 cells with 1 (30 μg/mL) or 0.1% DMSO were added to a monolayer of
WI26 cells in triplicate wells of 24-well plates, respectively. Adhering THP-1 cells after
3-h-incubation were counted in four random visual fields of each well. (A) The attachment
of THP-1 cells (marked by arrows) onto confluent WI26 cells, treated with 0.1% DMSO;
(B) The attachment of THP-1 cells onto confluent WI26 cells, treated with 1 (30 μg/mL). It
is clear from these images that adhesion of THP-1 cells was significantly blocked by 1.
Bar = 25 μm. Each point represents the mean ± SD of three independent experiments.
Significant difference from the value of 0.1% DMSO solvent control was marked,
* p < 0.05.
2.5. Effects of Compound 1 on Contraction of WI26 Cells in 3D Collagen Lattices
It is widely known that mechanical force plays a contributing role in inflammation and fibrotic
processes [19,20]. Not surprisingly, the contractible force generated by fibroblasts is a focus of much
research [21]. Activated fibroblasts express many stress fibers which can facilitate wound repair [3]
and fibrogenesis [22], while at the same time mechanical stress can promote inflammation and fibrosis
by activating fibroblasts and inflammation cells [19,23]. In order to evaluate the anti-contractility
activity of 1, three-dimensional collagen lattices were used as a richer, perhaps more physiologically
relevant physical environment, that can enable direct investigation of the interactive process of
fibroblast-collagen matrix remodeling [24]. WI26 cells were seeded in free-floating collagen gel
lattices, followed by the application of 1 or solvent control. As shown in Figure 5A, the presence of
compound 1 significantly delayed contraction of the collagen gel. After 1, 2, 3 and 6 h, the contraction
was markedly decreased compared to solvent control by 21%, 22%, 18% and 8%, respectively (Figure 5B).

Mar. Drugs 2012, 10
Figure 5. Compound 1 inhibited contractile ability of WI26 cells in 3D collagen lattices.
646
Equal numbers of WI26 cells were seeded in triplicate gels of collagen I with compound 1
(30 μg/mL) or 0.1% DMSO. The contraction of collagen gel was monitored by
photographing the gels at appointed time intervals. (A) As illustrated, contraction of
collagen gel was attenuated by compound 1 compared to 0.1% DMSO at different time
points. The edge of gel was marked with dots. (B) The area of the gel was measured and
plotted as a percentage of the original area at the onset of the experiments. Each point
represents the mean ± SD of three independent experiments. Significant differences from
the value of 0.1% DMSO solvent control were marked, * p < 0.05, ** p < 0.01.
2.6. Discussion
Today, fibrotic diseases are becoming more threathening than ever, due to enviromental pollution.
It has been reported that high levels of air pollutant paticles can induce chronic fibrotic responses in
airways [25]. Identification of bioactive molecules that affect fibrosis is thus becoming a promising
theraputic area and also an urgent task. For example, the synthetic drug TAS-301, a constrictive
remodeling regulator, was shown to have high inhibitory potency on coronary artery stenosis, mainly
due to inhibition of adventitial fibroblast proliferation and the contractile ability of myofibroblasts [26].
During excessive fibrogenesis, it is well known that self-perpetuating circuits of inflammation and
ECM accumulation, and constriction by inflammation and mechanical force, directly influence the
development of fibrotic diseases [4]. Hence, the development of leading compounds aimed at these
circuits may target the effects on these diseases, while avoiding severely disturbing physiological
processes induced by steroidal anti-inflammatory drugs.
Fibroblasts play pivotal roles in establishing and maintaining these circuits and are in fact the main
ECM generating cells in fibrotic diseases [27]. During these diseases, resident fibroblasts proliferate
and are activated as a result of stimulation by injury or inflammation. The activated fibroblasts contribute
to ECM production and inflammatory modulation [28]. Radiotherapy and chemotherapeutics are

Mar. Drugs 2012, 10
647
useful for treating hypertrophic scar and keloid development by inducing apoptosis of fibroblasts [29].
Compound 1 showed inhibitory effects on fibroblast proliferation, and thus may contribute to the
alleviation of excessive fibrotic accumulation.
Activated fibroblasts may also convert into myofibroblasts, which express many more stress fibers
and generate much more mechanical tension [1]. The mechanical force generated by endogenous
fibroblasts has been found to play important roles in the activation and secretion of inflammatory
cells [19,23,30]. It has been demonstrated that reduction of mechanical stress can alleviate
inflammation and fibrosis in vivo [12]. Therefore, mechanical force and local inflammation together
comprise one of the most important self-perpetuating inflammatory circuits that, underlies many
fibrotic diseases. Compound 1 can reduce the contractile capability of fibroblasts, thus indicating a
potential to inhibit this key aspect of fibrogenesis.
The interaction of monocytes and fibroblasts is known to play an important role in
inflammation [17,31]. Direct contact between monocytes and fibroblasts can faciliate the activation of
both cells [32]. Compound 1 blocked the adhesion of fibroblasts and monocytes, which may
ameliorate excessive inflammatory processes in fibrotic diseases. In previous investigation, 1 was
reported as an antagonist of the LFA-1/ICAM-1 interaction [14]. Since LFA-1/ICAM-1 can mediate
direct contact of inflammatory cells and fibroblasts [33], the LFA-1/ICAM-1 binding inhibitory effect
may explain the results of the adhesion experiment.
In conclusion, 1 has multiple biological effects on lung fibroblast properties, including proliferation,
contractile capacity and interaction with monocytes, which are likely to be involved in the
establishment of positive feedback circuits that lead to excessive fibrosis.
Although pathological fibrosis of different organs is common in many diseases [1], there are
presently very few therapeutic options [34]. Anti-inflammatory drugs such as corticosteroids can
prevent pathological fibrosis [29,35], but long-term use and high dosage are unsuitable owing to their
extensive adverse effects [36,37]. Superficial compression is useful for preventing the development of
skin hypertrophic scars [29], but this procedure cannot be used in visceral organs. The “vicious cycle”
of fibroproliferation is one of the most important characteristics of pathological fibrosis [19,23].
Hence, small molecules that target the positive feedback circuits may prove tremendously effective in
exhibiting antifibrotic activities without severe side effects. The results presented herein illustrate that
compound 1 may serve as a useful antifibrotic leading compound for treating pulmonary fibrosis and
other pathological fibrotic diseases.
3. Experimental Section
3.1. General
1H and 13C NMR spectra were recorded with Bruker DRX-500 and Avance III-600 NMR
spectrometers with the solvent as an internal standard (DMSO-d6 δ = 2.51 and 40.0 ppm, respectively).
Chemical shifts (δ) expressed in parts per million (ppm) and coupling constants (J) are reported in
Hertz (Hz). LC-HRMS was performed on a Waters ACQUITY UPLC system equipped with a binary
solvent delivery manager and a sample manager, coupled with a Waters Micromass Q-TOF Premier
Mass Spectrometer equipped with an electrospray interface (Waters Corporation, Milford, MA).

Mar. Drugs 2012, 10
648
Column chromatography was performed with silica gel (200–300 mesh, Qingdao Marine Chemical,
Inc., Qingdao, China), silica gel H (10–40 μm, Qingdao), Sephadex LH-20 (40–70 μm, Amersham
Pharmacia Biotech AB, Uppsala, Sweden) and Lichroprep reversed-phase RP-18 silica gel (40–63 μm,
Merck, Darmstadt, Germany). The chemical reagents used for chromatography were purchased from
Shanghai Chemical Works Co. Ltd. (Shanghai, China). Optical rotations were recorded on a JASCO
P-2000 polarimeter. CD spectra were taken on a J-815 spectropolarimeter (JASCO, Gross-Umstadt,
Germany) at room temperature. An Agilent 1200 series system was used for the analytical scale
method. Analytical HPLC was carried out on an Welch XB-C18 column (4.6 × 150 mm, 5 μm, Welch
Materials, Inc., USA), flow 1 mL/min. Organic solvents for HPLC were analytical grade and were
purchased from Shanghai ANPEL Scientific Instrument Co. Ltd. (Shanghai, China).
3.2. Strain Cultivation
Streptomyces xiamenensis strain 318 was isolated from a mangrove sediment sample collected in
the national mangrove reserve in Fujian province of China [13]. Spores of strain 318 were inoculated
on GYM (Glucose 4 g, Yeast extract 4 g, Malt extract 10 g, CaCO3 2 g, Agar 12 g, Distilled water 1 L,
adjusted to pH 7.2 with KOH before adding agar.) plates were then incubated at 28 ± 1 °C for 12 days
before harvesting.
3.3. Extraction and Isolation
The 30 L plate culture of S. xiamenisis was extracted with a solvent mixture of ethyl
acetate/methanol/acetic acid (80:15:5, v:v:v) at room temperature overnight. The supernatant was
filtered and the residue was then extracted twice as described above. The total supernatants were
combined and concentrated under vacuum at 37 °C in order to remove the organic part to afford a
crude extract (12 g). Half of the crude extract was subjected to column chromatography on silica gel,
eluted by CH2Cl2:MeOH (gradient from methanol, 100:1, 50:1, 20:1, 10:1, 5:1 to MeOH). The fraction
[eluted with CH2Cl2:MeOH (10:1, v:v)] was collected and purified by repeated column chromatography
on Sephadex LH-20, which was washed by MeOH. The fractions were collected and guided by HPLC
fingerprints to find peaks containing the target UV profile (λmax 206, 260 nm). Finally, the combination
was separated by ODS column (eluted with MeOH:H2O = 75:25) to obtain compound 1 (15 mg).
N-[[3,4-dihydro-3S-hydroxy-2S-methyl-2-(4′R-methyl-3′S-pentenyl)-2H-1-benzopyran-6-yl]
carbonyl]-threonine (1): Yellow amorphous powder (MeOH); [α]22 +39.5° (c 0.044, MeOH); UV
D
λmax (MeOH) 206, 260 nm; CD (MeOH) Δε201 +0.15, Δε202 +0.55, Δε205 +0.3, Δε207.5 +0.5,
1
Δε229 −0.05, Δε259 +0.28; H and 13C NMR data, see Table 1; HRESIMS m/z 392.2069 [M + H]+,
(calcd for C21H30NO6, m/z 392.2073), 390.1886 [M − H]−, (calcd for C21H29NO6, m/z 390.1917).
3.4. (R)- and (S)-MPA Esterification
(R)-MPA (4.0 mg), dicyclohexylcarbodiimide (DCC), and catalytic N,N-dimethylpyridin-4-amine
(DMAP) were added to a CHCl3 solution of compound 1. The mixture was stirred for 2 h to yield
(R)-MPA ester of 1. The (S)-MPA ester (1.1 mg) was obtained by the same protocol as for (R)-MPA
ester (1.2 mg).

Mar. Drugs 2012, 10
649
3.5. Hydrolysis of Compound 1, Derivatization with Marfey’s Reagent
Compound 1 (1.0 mg) was hydrolyzed in 1:1 hydrochloric acid-acetic acid at 100 °C for 18 h,
500 μL H2O was added and the mixture was lyophilized overnight [16]. Then 200 μL of 1 M NaHCO3
and 400 μL of 38.7 μM FDAA (Sigma-Aldrich, St. Louise, MO, USA) in acetone were added to the
mixture for derivatization. The solution was vortexed and incubated at 40 °C for 60 min. Reactions
were quenched by addition of 100 μL of 2M HCl. Samples were diluted 1:2 with HPLC initial mobile
phase. The derivatization of L-Threonine (Sangon, Shanghai, China) and D-Threonine (Sangon,
Shanghai, China) were prepared in the same way. Then the samples were analyzed by HPLC with UV
detection at 340 nm and further confirmed by UPLC-MS.
3.6. Cell Culture
The WI26-SV40 transformed human lung fibroblast [American Type Culture Collection (ATCC)
CCL 95.1] cells were maintained in Dulbecco's Modified Eagle Medium (DMEM, Gibco, Grand
Island, NY, USA) supplemented with 10% fetal bovine serum (FBS, GIBCO-BRL, Gaithersburg, MD,
USA), 2 mM L-glutamine, 100 U/mL penicillin and 100 μg/mL streptomycin (Solarbio, Beijing, China).
THP-1 (human acute monocytic leukemia cell line) cells were maintained in RPMI 1640 meted with
10% fetal bovine serum (FBS, GIBCO-BRL, Gaithersburg, MD, USA), 2 mM L-glutamine, 100 U/mL
penicillin and 100 μg/mL streptomycin (Solarbio, Beijing, China). THP-1 (human acute monocytic
leukemia cell line) cells were maintained in RPMI 1640 medium (Gibco, Grand Island, NY, USA),
supplemented with 10% FBS, 2 mM L-glutamine, 100 U/mL penicillin, 100 μg/mL streptomycin, and
0.5 mM/L β-mercaptoethanol (Gibco, Grand Island, NY, USA). Both kinds of cells were incubated at
37 °C humidified atmosphere of 5% CO2 in air.
3.7. Cell Proliferation Assay
The effect of compound 1 on cell proliferation was determined using a standard Cell Counting
Kit-8 (CCK-8, Dojindo, Kumamoto, Japan) assay according to the manufacturer’s instruction. WI26
cells at 70%–80% confluent were trysinized by 0.25% trypsin-0.02% EDTA solution, centrifuged and
re-suspended in DMEM supplemented with 10% FBS and antibiotics and seeded in 96-well plates
(100 μL/well) at an initial density of 2.5 × 104 cells/mL. The medium was replaced 24 h later by fresh
DMEM with 10% FBS and antibiotics containing 30 μg/mL compound 1 or 0.1% DMSO (AppliChem,
Darmstadt, Germany), then the medium was refreshed and the cells viability was measured by using
CCK-8 solution at day 0, 2, 3, 4 and 6, respectively. Proliferation measurement was applied by adding
10 μL CCK-8 solutions to each well and incubating at 37 °C for 1 h. The OD values of each well were
measured at the primary wavelength λ = 450 nm by using a Microplate Spectrophotometer
(PowerWaveXS, BioTek, Seattle, WA, USA). Data are shown as means ± standard deviation (SD) of
three independent experiments, each performed in triplicate.
3.8. Cell Adhesion Assay
Two days before adhesion assay, WI26 cells were seeded in 24-well plates (500 μL/well) at a
density of 3 × 105 cells/mL and allowed to grow 24 h to confluence. The medium of THP-1 and WI26

Mar. Drugs 2012, 10
650
cells was replaced by DMEM supplemented with 0.5% FBS and antibiotics 24 h before the adhesion
experiment. The culture of THP-1 cells was centrifuged at 1000 rpm for 5 min. The supernatant was
discarded. The THP-1 cells were re-suspended in DMEM with 10% FBS and antibiotics, then diluted
to 5 × 105 cells/mL. The medium of WI26 cells in 24-well plates was discarded to get a monolayer of
WI26 cells in each well, then 500 μL THP-1 suspension was added into each well as previously
published [38,39]. For the biotest groups, 30 μg/mL compound 1 or 50 μg/mL crude extract of
S. xiamenensis culture was added in each well, respectively. For the control groups, 0.1% DMSO was
used as solvent control for 1 and 0.01% DMSO as solvent control of crude extract, respectively,
according to the different final DMSO concentration of 1 and crude extract. Two kinds of cells were
co-cultured for 3 h, then the medium and the non-adherent THP-1 cells were removed by washing with
PBS three times. Adherent THP-1 cells were quantified microscopically at 400-fold magnification in 4
random visual fields of each well and photographed with a digital camera (LY-WN-HPCCD, China)
mounted on a microscope (Olympus, CKX31, Japan). Data are shown as means ± standard deviation
(SD) of three independent experiments, each performed in triplicate.
3.9. Fibroblast Contraction Assay
WI26 cells at 70%–80% confluent were trysinized by 0.25% trypsin-0.02% EDTA solution and
seeded at a density of 4 × 105 cells/mL into 32 mm bacteriological plates (2 mL/dish) in DMEM
supplemented with 10% FBS, antibiotics, sodium ascorbate (50 μg/mL), and containing 0.3 mg/mL of
acid-extracted collagen I from newborn calf skin (IBFB, Leipzig, Germany) as previously
described [40]. For the biotest groups, 30 μg/mL pure extract of compound 1 was added in each well;
for the control groups, 0.1% DMSO was used as solvent control. The cultures were placed at 37 °C for
60 min to allow collagen polymerization, and then the gels from plates were released by tilting the
plates slightly. Gradual lattice contraction was monitored by measuring the gel area of triplicate setups
at successive time points up to 6 h. Data are shown as means ± standard deviation (SD) of three
independent experiments, each performed in triplicate.
3.10. Statistical Analysis
Statistic differences were calculated using student’s paired t-test at a significance level of p < 0.05
to 0.001.
3.11. Computational Methods
The QM calculations were carried out with the M06-2X hybrid meta DFT functional with the
6 − 31 + G(d,p) basis set using Gaussian 09. Conformations were fully optimized and characterized by
harmonic vibrational frequency analysis. The solvation energies in DMSO were calculated with
Truhlar’s SMD solvation model [41–43].
4. Conclusions
The investigation of anti-fibrosis small molecules derived from S. xiamenensis may represent an
emerging pharmacological and therapeutic area for fibrotic diseases. The structure and

Mar. Drugs 2012, 10
651
absolute configurations of N-[[3,4-dihydro-3S-hydroxy-2S-methyl-2-(4′R-methyl-3′S-pentenyl)-2H-1-
benzopyran-6-yl]carbonyl]-threonine (1) was fully elucidated by extensive spectroscopic data analyses,
Mosher’s method, Marfey’s reagent and QM calculations. The multiple biological effects of 1 on lung
fibroblast behavior were investigated, including proliferation, anti-contractile capacity and anti-adhesion
with monocytes. These three bioactive aspects are involved in the construction of positive feedback
circuits of excessive fibrosis. Developing leading compounds from marine natural products, aiming at
these circuits may have targeted effects on fibrotic diseases.
Acknowledgments
We are grateful to Zhiwei Deng in Analytical and Testing Center of Beijing Normal University, and
Jieli Wu in Instrumental Analysis Center of Shanghai Jiao Tong University for technical support
during the NMR measurement. We are also grateful to Lei Feng and Na Zhu in Instrumental Analysis
Center of Shanghai Jiao Tong University for the HRESIMS and UPLC-MS measurements. I am very
thankful to Daniel M. Czajkowsky for the English correction. The work was supported by grants from
the National Science Foundation of China (30901845, 91029738, 3082105), the National Basic
Research Program of China “973” 2012CB72100 and the grants from the State Key Laboratory of
Oncogenes and Related Genes (No. 90-10-11). The project was also sponsored by SRF for ROCS,
SEM SHSTC (10PJ1405200), SHEC (SOS-0900000171) and by Research Fund for the New Teacher
Program of Higher Education of China (20090001120047).
References
1. Wynn, T.A. Cellular and molecular mechanisms of fibrosis. J. Pathol. 2008, 214, 199–210.
2. Borm, P. Toxicity of Selected: Toxicology of Fibers and Particles; John Wiley & Sons Ltd.:
Hoboken, NJ, USA, 2008.
3. Gurtner, G.C.; Werner, S.; Barrandon, Y.; Longaker, M.T. Wound repair and regeneration. Nature
2008, 453, 314–321.
4. Nathan, C.; Ding, A.H. Nonresolving Inflammation. Cell 2010, 140, 871–882.
5. Guan, S.; Grabley, S.; Groth, I.; Lin, W.; Christner, A.; Guo, D.; Sattler, I. Structure determination
of germacrane-type sesquiterpene alcohols from an endophyte Streptomyces griseus subsp. Magn.
Reson. Chem. 2005, 43, 1028–1031.
6. Guan, S.H.; Sattler, I.; Lin, W.H.; Guo, D.A.; Grabley, S. p-Aminoacetophenonic acids produced
by a mangrove endophyte: Streptomyces griseus subsp. J. Nat. Prod. 2005, 68, 1198–1200.
7. Lin, W.; Li, L.; Fu, H.; Sattler, I.; Huang, X.; Grabley, S. New cyclopentenone derivatives from an
endophytic Streptomyces sp. isolated from the mangrove plant Aegiceras comiculatum. J. Antibiot.
(Tokyo) 2005, 58, 594–598.
8. Wang, F.; Xu, M.; Li, Q.; Sattler, I.; Lin, W. p-Aminoacetophenonic acids produced by a
mangrove endophyte Streptomyces sp. (strain HK10552). Molecules 2010, 15, 2782–2790.
9. Xu, M.; Gessner, G.; Groth, I.; Lange, C.; Christner, A.; Bruhn, T.; Deng, Z.; Li, X.;
Heinemann, S.H.; Grabley, S.; et al. Shearinines D–K, new indole triterpenoids from an
endophytic Penicillium sp. (strain HKI0459) with blocking activity on large-conductance
calcium-activated potassium channels. Tetrahedron 2007, 63, 435–444.

Mar. Drugs 2012, 10
652
10. Ravangpai, W.; Sommit, D.; Teerawatananond, T.; Sinpranee, N.; Palaga, T.; Pengpreecha, S.;
Muangsin, N.; Pudhom, K. Limonoids from seeds of Thai Xylocarpus moluccensis. Bioorg. Med.
Chem. Lett. 2011, 21, 4485–4489.
11. Li, Y.; Liu, J.; Yu, S.; Proksch, P.; Gu, J.; Lin, W. TNF-alpha inhibitory diterpenoids from the
Chinese mangrove plant Excoecaria agallocha L. Phytochemistry 2010, 71, 2124–2131.
12. Gurtner, G.C.; Dauskardt, R.H.; Wong, V.W.; Bhatt, K.A.; Wu, K.; Vial, I.N.; Padois, K.;
Korman, J.M.; Longaker, M.T. Improving cutaneous scar formation by controlling the mechanical
environment: Large animal and phase I studies. Ann. Surg. 2011, 254, 217–225.
13. Xu, J.; Wang, Y.; Xie, S.J.; Xu, J.; Xiao, J.; Ruan, J.S. Streptomyces xiamenensis sp. nov., isolated
from mangrove sediment. Int. J. Syst. Evol. Microbiol. 2009, 59, 472–476.
14. Kawamura, N.; Tsuji, E.; Watanabe, Y.; Tsuchihashi, K.; Takako, T. Benzopyran derivatives, their
manufacture with Streptomyces species, and their use for treatment of asthma and rheumatoid
arthritis; Daiichi Seiyaku Co., Ltd.; Mercian Corp.: Kyoto, Japan, 7 March 2000.
15. Plavec, J.; Tong, W.; Chattopadhyaya, J. How do the gauche and anomeric effects drive the
pseudorotational equilibrium of the pentofuranose moiety of nucleosides? J. Am. Chem. Soc. 1993,
115, 9734–9746.
16. Goodlett, D.R.; Abuaf, P.A.; Savage, P.A.; Kowalski, K.A.; Mukherjee, T.K.; Tolan, J.W.;
Corkum, N.; Goldstein, G.; Crowther, J.B. Peptide chiral purity determination: Hydrolysis in
deuterated acid, derivatization with Marfey’s reagent and analysis using high-performance
liquid chromatography-electrospray ionization-mass spectrometry. J. Chromatogr. A 1995, 707,
233–244.
17. Wynn, T.A.; Barron, L. Macrophages: Master regulators of inflammation and fibrosis. Semin.
Liver Dis. 2010, 30, 245–257.
18. Barron, L.; Wynn, T.A. Fibrosis is regulated by Th2 and Th17 responses and by dynamic
interactions between fibroblasts and macrophages. Am. J. Physiol. Gastrointest. Liver Physiol.
2011, 300, G723–G728.
19. Wong, V.W.; Rustad, K.C.; Akaishi, S.; Sorkin, M.; Glotzbach, J.P.; Januszyk, M.; Nelson, E.R.;
Levi, K.; Paterno, J.; Vial, I.N.; et al. Focal adhesion kinase links mechanical force to skin fibrosis
via inflammatory signaling. Nat. Med. 2011, doi:10.1038/nm.2574.
20. Oakes, P.W.; Patel, D.C.; Morin, N.A.; Zitterbart, D.P.; Fabry, B.; Reichner, J.S.; Tang, J.X.
Neutrophil morphology and migration are affected by substrate elasticity. Blood 2009, 114,
1387–1395.
21. Wong, V.W.; Akaishi, S.; Longaker, M.T.; Gurtner, G.C. Pushing back: Wound
mechanotransduction in repair and regeneration. J. Investig. Dermatol. 2011, 131, 2186–2196.
22. Abraham, D.J.; Eckes, B.; Rajkumar, V.; Krieg, T. New developments in fibroblast and
myofibroblast biology: Implications for fibrosis and scleroderma. Curr. Rheumatol. Rep. 2007, 9,
136–143.
23. Wong, V.W.; Paterno, J.; Sorkin, M.; Glotzbach, J.P.; Levi, K.; Januszyk, M.; Rustad, K.C.;
Longaker, M.T.; Gurtner, G.C. Mechanical force prolongs acute inflammation via
T-cell-dependent pathways during scar formation. FASEB J. 2011, doi:10.1096/fj.10-178087.
24. Grinnell, F. Fibroblast biology in three-dimensional collagen matrices. Trends Cell Biol. 2003, 13,
264–269.

Mar. Drugs 2012, 10
653
25. Churg, A.; Brauer, M. Ambient atmospheric particles in the airways of human lungs. Ultrastruct.
Pathol. 2000, 24, 353–361.
26. Sasaki, E.; Tanahashi, Y.; Yamasaki, Y.; Oda, N.; Nozawa, Y.; Terakawa, H.; Miyoshi, K.;
Muranaka, Y.; Miyake, H.; Matsuura, N. Inhibitory effect of TAS-301, a new synthesized
constrictive remodeling regulator, on renarrowing after balloon overstretch injury of porcine
coronary artery. J. Pharmacol. Exp. Ther. 2000, 295, 1043–1050.
27. Eckes, B.; Nischt, R.; Krieg, T. Cell-matrix interactions in dermal repair and scarring.
Fibrogenesis Tissue Repair 2010, 3, doi:10.1186/1755-1536-3-4.
28. Strieter, R.M.; Gomperts, B.N.; Keane, M.P. The role of CXC chemokines in pulmonary fibrosis.
J. Clin. Investig. 2007, 117, 549–556.
29. Wolfram, D.; Tzankov, A.; Pulzl, P.; Piza-Katzer, H. Hypertrophic scars and keloids—A review of
their pathophysiology, risk factors, and therapeutic management. Dermatol. Surg. 2009, 35,
171–181.
30. Laurent, G.J.; Chambers, R.C.; Hill, M.R.; McAnulty, R.J. Regulation of matrix turnover:
Fibroblasts, forces, factors and fibrosis. Biochem. Soc. Trans. 2007, 35, 647–651.
31. Delavary, B.M.; van der Veer, W.M.; van Egmond, M.; Niessen, F.B.; Beelen, R.H. Macrophages
in skin injury and repair. Immunobiology 2011, 216, 753–762.
32. Holt, D.J.; Chamberlain, L.M.; Grainger, D.W. Cell-cell signaling in co-cultures of macrophages
and fibroblasts. Biomaterials 2010, 31, 9382–9394.
33. Long, E.O. ICAM-1: Getting a grip on leukocyte adhesion. J. Immunol. 2011, 186, 5021–5023.
34. Kelemen, O.; Kollar, L. Current methods of treatment and prevention of pathologic scars. Magy.
Seb. 2007, 60, 63–70.
35. Ogawa, R. The most current algorithms for the treatment and prevention of hypertrophic scars and
keloids. Plast. Reconstruct. Surg. 2010, 125, 557–568.
36. Cheng, K.; Ashby, D.; Smyth, R.L. Oral steroids for long-term use in cystic fibrosis. Cochrane
Database Syst. Rev. 2011, doi:10.1002/14651858.
37. Hunzelmann, N.; Moinzadeh, P.; Genth, E.; Krieg, T.; Lehmacher, W.; Melchers, I.; Meurer, M.;
Müller-Ladner, U.; Olski, T.M.; Pfeiffer, C.; et al. High frequency of corticosteroid and
immunosuppressive therapy in patients with systemic sclerosis despite limited evidence for
efficacy. Arthritis Res. Ther. 2009, 11, doi:10.1186/ar2634.
38. Pfaff, A.W.; Georges, S.; Candolfi, E. Different effect of Toxoplasma gondii infection on adhesion
capacity of fibroblasts and monocytes. Parasite Immunol. 2008, 30, 487–490.
39. Taub, D.D.; Lloyd, A.R.; Conlon, K.; Wang, J.M.; Ortaldo, J.R.; Harada, A.; Matsushima, K.;
Kelvin, D.J.; Oppenheim, J.J. Recombinant human interferon-inducible protein 10 is a
chemoattractant for human monocytes and T lymphocytes and promotes T cell adhesion to
endothelial cells. J. Exp. Med. 1993, 177, 1809–1814.
40. Zhang, Z.G.; Bothe, I.; Hirche, F.; Zweers, M.; Gullberg, D.; Pfitzer, G.; Krieg, T.; Eckes, B.;
Aumailley, M. Interactions of primary fibroblasts and keratinocytes with extracellular matrix
proteins: Contribution of α2β1 integrin. J. Cell Sci. 2006, 119, 1886–1895.
41. Gaussian 9, Revision A.02; Gaussian, Inc.:Wallingford, CT, USA, 2009.
42. Zhao, Y.; Truhlar, D.G. Density functionals with broad applicability in chemistry. Acc. Chem. Res.
2008, 41, 157–167.

Mar. Drugs 2012, 10
654
43. Marenich, A.V.; Cramer, C.J.; Truhlar, D.G. Universal solvation model based on solute electron
density and on a continuum model of the solvent defined by the bulk dielectric constant and
atomic surface tensions. J. Phys. Chem. B 2009, 113, 6378–6396.
Sample Availability: Sample of compound 1 is available from authors.
© 2012 by the authors; license MDPI, Basel, Switzerland. This article is an open access article
distributed under the terms and conditions of the Creative Commons Attribution license
(http://creativecommons.org/licenses/by/3.0/).